Access the full text.
Sign up today, get DeepDyve free for 14 days.
Diana Superfin, A. Iannucci, A. Davies (2007)
Commentary: Oncologic drugs in patients with organ dysfunction: a summary.The oncologist, 12 9
O. Olafiranye, G. Jean-Louis, F. Zizi, J. Nunes, M. Vincent (2011)
Anxiety and cardiovascular risk: Review of Epidemiological and Clinical Evidence.Mind & brain : the journal of psychiatry, 2 1
Jesse Stewart, A. Perkins, C. Callahan (2014)
Effect of Collaborative Care for Depression on Risk of Cardiovascular Events: Data From the IMPACT Randomized Controlled TrialPsychosomatic Medicine, 76
R. Griffiths, Matthew Johnson, M. Carducci, A. Umbricht, W. Richards, Brian Richards, Mary Cosimano, Margaret Klinedinst (2016)
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trialJournal of Psychopharmacology (Oxford, England), 30
P. Hippel (2015)
The heterogeneity statistic I2 can be biased in small meta-analysesBMC Medical Research Methodology, 15
A. Risal, K. Manandhar, M. Linde, R. Koju, T. Steiner, A. Holen (2014)
Reliability and Validity of a Nepali-language Version of the Hospital Anxiety and Depression Scale (HADS).Kathmandu University medical journal, 13 50
S. Grof, L. Goodman, W. Richards, A. Kurland (1973)
LSD-assisted psychotherapy in patients with terminal cancer.International pharmacopsychiatry, 8 3
J. Higgins, S. Thompson (2002)
Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 21
Dudas (2018)
CD003944Cochrane Database Syst Rev, 8
Olafiranye (2011)
32Mind Brain, 2
M. Page, D. Moher, P. Bossuyt, I. Boutron, T. Hoffmann, C. Mulrow, Larissa Shamseer, J. Tetzlaff, E. Akl, S. Brennan, R. Chou, Julie Glanville, J. Grimshaw, A. Hrõbjartsson, M. Lalu, Tianjing Li, E. Loder, E. Mayo-Wilson, Steve McDonald, L. McGuinness, L. Stewart, James Thomas, A. Tricco, V. Welch, P. Whiting, J. McKenzie (2020)
PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviewsThe BMJ, 372
Mc Bride (2007)
465Conn Med, 71
C. Grob, A. Danforth, G. Chopra, M. Hagerty, C. McKay, A. Halberstadt, G. Greer (2011)
Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.Archives of general psychiatry, 68 1
Collin Reiff, Elon Richman, C. Nemeroff, L. Carpenter, A. Widge, C. Rodriguez, N. Kalin, W. McDonald (2020)
Psychedelics and Psychedelic-Assisted Psychotherapy.The American journal of psychiatry
(2022)
Copelin EL Hypertensive Urgency
J. Bains, J. Birks, T. Dening (2002)
Antidepressants for treating depression in dementia.The Cochrane database of systematic reviews, 4
M. Hamilton (1960)
A RATING SCALE FOR DEPRESSIONJournal of Neurology, Neurosurgery & Psychiatry, 23
Consulting Psychologists Press
Marissa Salvo, C. White (2014)
Reconciling Multiple Hypertension Guidelines to Promote Effective Clinical PracticeAnnals of Pharmacotherapy, 48
J. Sterne, J. Savović, M. Page, R. Elbers, N. Blencowe, I. Boutron, C. Cates, Hung-Yuan Cheng, M. Corbett, S. Eldridge, J. Emberson, M. Hernán, S. Hopewell, A. Hrõbjartsson, D. Junqueira, P. Jüni, J. Kirkham, T. Lasserson, Tianjing Li, A. McAleenan, B. Reeves, S. Shepperd, I. Shrier, L. Stewart, K. Tilling, I. White, P. Whiting, J. Higgins (2019)
RoB 2: a revised tool for assessing risk of bias in randomised trialsBMJ, 366
Peter Gasser, Dominique Holstein, Y. Michel, R. Doblin, B. Yazar-Klosinski, T. Passie, R. Brenneisen (2014)
Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening DiseasesThe Journal of Nervous and Mental Disease, 202
K. Kuypers (2020)
The therapeutic potential of microdosing psychedelics in depressionTherapeutic Advances in Psychopharmacology, 10
Thomas Anderson, Rotem Petranker, Adam Christopher, Dan Rosenbaum, C. Weissman, L. Dinh-Williams, Katrina Hui, Emma Hapke (2019)
Psychedelic microdosing benefits and challenges: an empirical codebookHarm Reduction Journal, 16
V. Kamanna, S. Ganji, M. Kashyap (2009)
The mechanism and mitigation of niacin-induced flushingInternational Journal of Clinical Practice, 63
Michael White (2014)
How MDMA's Pharmacology and Pharmacokinetics Drive Desired Effects and HarmsThe Journal of Clinical Pharmacology, 54
M. Tomsovic, Robert Edwards (1970)
Lysergide treatment of schizophrenic and nonschizophrenic alcoholics: a controlled evaluation.Quarterly journal of studies on alcohol, 31 4
C. White (2017)
The Pharmacologic and Clinical Effects of Illicit Synthetic CannabinoidsThe Journal of Clinical Pharmacology, 57
G. Knapp, J. Hartung (2003)
Improved tests for a random effects meta‐regression with a single covariateStatistics in Medicine, 22
P. Spinhoven, B. Penninx, A. Hemert, M. Rooij, B. Elzinga (2014)
Comorbidity of PTSD in anxiety and depressive disorders: prevalence and shared risk factors.Child abuse & neglect, 38 8
B. Bride, J. Kalus, D. Guertin, Krista Dale, J. Kluger, C. White (2007)
Impact of catecholamines on the QTc interval in patients at high risk of sudden death.Connecticut medicine, 71 8
Philip Wolfson, Julane Andries, A. Feduccia, L. Jerome, Julie Wang, Emily Williams, Shannon Carlin, Evan Sola, S. Hamilton, B. Yazar-Klosinski, A. Emerson, M. Mithoefer, R. Doblin (2020)
MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot studyScientific Reports, 10
Kimberly Smith, Dakota Sicignano, Adrian Hernández, C. White (2021)
MDMA‐Assisted Psychotherapy for Treatment of Posttraumatic Stress Disorder: A Systematic Review With Meta‐AnalysisThe Journal of Clinical Pharmacology, 62
Robbie Aert, D. Jackson (2019)
A new justification of the Hartung‐Knapp method for random‐effects meta‐analysis based on weighted least squares regressionResearch Synthesis Methods, 10
Beck's Depression Inventory
E. Park, S. Gelber, Shoshana Rosenberg, D. Seah, L. Schapira, S. Come, A. Partridge (2018)
Anxiety and Depression in Young Women With Metastatic Breast Cancer: A Cross-Sectional Study.Psychosomatics, 59 3
Stephen Ross, Anthony Bossis, Jeffrey Guss, G. Agin-Liebes, T. Malone, Barry Cohen, S. Mennenga, Alexander Belser, K. Kalliontzi, J. Babb, Zhe Su, P. Corby, B. Schmidt (2016)
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trialJournal of Psychopharmacology (Oxford, England), 30
M. Zimmerman, Jennifer Martinez, Diane Young, I. Chelminski, Kristy Dalrymple (2013)
Severity classification on the Hamilton Depression Rating Scale.Journal of affective disorders, 150 2
Sterne (2019)
1BMJ, 366
Objectives: Life-threatening cancer or other diseases can induce anxiety and depressive symptoms. We performed a systematic review with meta-analyses of randomized controlled trials assessing patients with cancer or other life-threatening diseases using validated anxiety and depression scales. Methods: PubMed was searched up to November 15, 2022 and citations were applied to prespecified inclusion criteria. Disease rating scales for anxiety or depression included the State-Trait Anxiety Inventory (STAI) (STAI Trait [STAI-T], STAI-State [STAI-S]), Beck Depression Inventory (BDI), Hospital Anxiety and Depression Scale (HADS) (HADS-Anxiety [HADS-A]; HADS-Depression [HADS-D]), Profile of Mood States (POMS), and the Hamilton Rating Scale for Depression (HAM-D or GRID-HAM-D-17). Safety outcomes included assessments of blood pressure and heart rate. Results: Five trials, predominantly in cancer patients, had data assessing anxiety and depressive symptoms. These trials found promising results for psychedelics versus placebo in several anxiety and depression scales but increases in blood pressure and heart rate also occurred. There were some concerns of risk of bias because it is difficult to truly randomize a psychedelic trial and there was a high percentage of patients in the trials who had used psychedelics in the past. There was high heterogeneity for all analyses that we could not explain. Conclusions: Although the results are promising, future trials are needed to assess the optimal psychedelic, dose, number of sessions required, and how psychedelic naïve patients would respond both psychologically and hemodynamically before this therapy can be considered for widescale clinical use.
American Journal of Clinical Oncology – Wolters Kluwer Health
Published: Jun 13, 2023
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.